Treatment-Resistant Severe, Active Graves' Ophthalmopathy Successfully Treated with B Lymphocyte Depletion

Abstract

ThyroidVol. 16, No. 7 Letters to the EditorTreatment-Resistant Severe, Active Graves' Ophthalmopathy Successfully Treated with B Lymphocyte DepletionDaniel El Fassi, Claus H. Nielsen, Hans C. Hasselbalch, and Laszlo HegedüsDaniel El FassiSearch for more papers by this author, Claus H. NielsenSearch for more papers by this author, Hans C. HasselbalchSearch for more papers by this author, and Laszlo HegedüsSearch for more papers by this authorPublished Online:4 Aug 2006https://doi.org/10.1089/thy.2006.16.709AboutSectionsPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail "Treatment-Resistant Severe, Active Graves' Ophthalmopathy Successfully Treated with B Lymphocyte Depletion." , 16(7), pp. 709–710FiguresReferencesRelatedDetailsCited byObservation study of using a small dose of rituximab treatment for thyroid-associated ophthalmopathy in seven Chinese patients: One pilot study18 January 2023 | Frontiers in Endocrinology, Vol. 13Monoclonal Antibodies for the Treatment of Graves Orbitopathy: Precision Medicine?18 January 2023 | Ophthalmic Plastic & Reconstructive Surgery, Vol. Publish Ahead of PrintUnderstanding Pathogenesis Intersects With Effective Treatment for Thyroid Eye Disease8 August 2022 | The Journal of Clinical Endocrinology & Metabolism, Vol. 107, No. Supplement_1Rituximab for thyroid-associated ophthalmopathy16 June 2022 | Cochrane Database of Systematic Reviews, Vol. 2022, No. 6Medical treatment in thyroid eye disease in 202023 May 2020 | British Journal of Ophthalmology, Vol. 105, No. 3Pathogenesis and Medical Management of Thyroid Eye Disease5 August 2020Use of Rituximab After Orbital Decompression Surgery in Two Grave’s Ophthalmopathy Patients Progressing to Optic Neuropathy26 October 2020 | Frontiers in Endocrinology, Vol. 11Treatment strategies for Graves’ ophthalmopathy: a network meta-analysis4 July 2019 | British Journal of Ophthalmology, Vol. 104, No. 4Thyroid-associated ophthalmopathy: Emergence of teprotumumab as a promising medical therapyBest Practice & Research Clinical Endocrinology & Metabolism, Vol. 34, No. 1Teprotumumab Treatment for Thyroid-Associated Ophthalmopathy13 July 2020 | European Thyroid Journal, Vol. 9, No. Suppl. 1Zirconium-89-labelled rituximab PET-CT in orbital inflammatory disease30 July 2019 | EJNMMI Research, Vol. 9, No. 1Low-Dose Rituximab for Active Moderate to Severe Graves’ Orbitopathy Resistant to Conventional Treatment13 April 2018 | Ocular Immunology and Inflammation, Vol. 27, No. 5Early low‐dose rituximab for active thyroid eye disease: An effective and well‐tolerated treatment11 April 2019 | Clinical Endocrinology, Vol. 5Adjuvant rituximab, a potential treatment for the young patient with Graves’ hyperthyroidism (RiGD): study protocol for a single-arm, single-stage, phase II trial21 January 2019 | BMJ Open, Vol. 9, No. 1Rituximab: a novel treatment for refractory Riedel’s thyroiditisEndocrinology, Diabetes & Metabolism Case Reports, Vol. 2018Thyroid AutoimmunityRituximab therapy in steroid resistant thyroid associated ophthalmopathy8 April 2017 | Case Reports International, Vol. 6, No. 1Advances in treatment of active, moderate-to-severe Graves' ophthalmopathyThe Lancet Diabetes & Endocrinology, Vol. 5, No. 2MANAGEMENT OF ENDOCRINE DISEASE: Rituximab therapy for Graves’ orbitopathy – lessons from randomized control trialsEuropean Journal of Endocrinology, Vol. 176, No. 2Management of Dysthyroid Optic Neuropathy17 December 2016The Efficacy of Rituximab Combined with 131I for Ophthalmic Outcomes of Graves' Ophthalmopathy Patients4 January 2017 | Pharmacology, Vol. 99, No. 3-4Recent advances in understanding autoimmune thyroid disease: the tallest tree in the forest of polyautoimmunity28 September 2017 | F1000Research, Vol. 6THERAPY OF ENDOCRINE DISEASE: Endocrine dilemma: management of Graves’ orbitopathyEuropean Journal of Endocrinology, Vol. 175, No. 3Advances in the pharmacological treatment of Graves’ orbitopathy27 March 2016 | Expert Review of Clinical Pharmacology, Vol. 9, No. 7Therapeutic innovations in endocrine diseases – Part 5: Rituximab and graves’ orbitopathyLa Presse Médicale, Vol. 45, No. 6Radiotherapy for Graves’ disease. The possible role of low-dose radiotherapyReports of Practical Oncology & Radiotherapy, Vol. 21, No. 3Graves’ OphthalmopathyRituximab in the Treatment of Thyroid Eye Disease: A Review17 June 2015 | Neuro-Ophthalmology, Vol. 39, No. 3Intraorbital injection of rituximab versus high dose of systemic glucocorticoids in the treatment of thyroid-associated orbitopathy1 June 2014 | Endocrine, Vol. 48, No. 1Induction of thyroid remission using rituximab in a patient with type 3 autoimmune polyglandular syndrome including Graves’ disease and type 1 diabetes mellitus: A case reportEndocrine Journal, Vol. 62, No. 1Thyroid Eye Disease: A Comprehensive ReviewRapid response to and long-term effectiveness of anti-CD20 antibody in conventional therapy resistant Graves’ orbitopathy: A five-year follow-up study21 July 2014 | Autoimmunity, Vol. 47, No. 8Teprotumumab, an IGF-1R Blocking Monoclonal Antibody Inhibits TSH and IGF-1 Action in FibrocytesThe Journal of Clinical Endocrinology & Metabolism, Vol. 99, No. 9Novel treatment opportunities in Graves’ orbitopathyOrvosi Hetilap, Vol. 155, No. 33Thyroid Eye DiseaseJournal of Neuro-Ophthalmology, Vol. 34, No. 2Breaking Tolerance to Thyroid Antigens: Changing Concepts in Thyroid Autoimmunity3 October 2013 | Endocrine Reviews, Vol. 35, No. 1The effect of B cell depletion therapy on anti-TSH receptor antibodies and clinical outcome in glucocorticoid-refractory Graves' orbitopathy11 May 2013 | Clinical Endocrinology, Vol. 79, No. 3Rituximab for thyroid-associated ophthalmopathy31 May 2013 | Cochrane Database of Systematic Reviews, Vol. 92B-Cell Targeted Therapy With Rituximab for Thyroid Eye Disease: Closer to the ClinicSurvey of Ophthalmology, Vol. 58, No. 3Immune manipulation for Graves' disease: Re-exploring an unfulfilled promise with modern translational researchEuropean Journal of Internal Medicine, Vol. 23, No. 8Diabetes Mellitus tipo 1 e hepatite autoimune como forma de apresentação precoce da síndrome poliglandular autoimune tipo IIRevista Portuguesa de Endocrinologia, Diabetes e Metabolismo, Vol. 7, No. 2Treating the thyroid in the presence of Graves’ ophthalmopathyBest Practice & Research Clinical Endocrinology & Metabolism, Vol. 26, No. 3Immunotherapy in Miscellaneous Medical Disorders Graves Ophthalmopathy, Asthma, and Regional Painful SyndromeMedical Clinics of North America, Vol. 96, No. 3The Evaluation and Treatment of Graves OphthalmopathyMedical Clinics of North America, Vol. 96, No. 2Pathogenesis and Medical Management of Thyroid Eye Disease16 December 2011Treatment of mild to moderate Graves' ophthalmopathy with sodium diclofenac: a pilot studyArquivos Brasileiros de Endocrinologia & Metabologia, Vol. 55, No. 9Rituximab for thyroid-associated ophthalmopathy10 August 2011The Dilemma of How to Manage Graves' Hyperthyroidism in Patients with Associated OrbitopathyThe Journal of Clinical Endocrinology & Metabolism, Vol. 96, No. 3Thyroid-associated orbitopathy: Current insights into the pathophysiology, immunology and managementSaudi Journal of Ophthalmology, Vol. 25, No. 1Targeted biological therapies for Graves’ disease and thyroid-associated ophthalmopathy. Focus on B-cell depletion with Rituximab15 December 2010 | Clinical Endocrinology, Vol. 74, No. 1Rituximab for Thyroid Eye DiseaseOphthalmic Plastic & Reconstructive Surgery, Vol. 26, No. 5Treatment of Thyroid-Associated Orbitopathy With Rituximab—A Novel Therapy for an Old Disease: Case Report and Literature ReviewEndocrine Practice, Vol. 16, No. 4Pathogenesis of Graves’ orbitopathy: A 2010 update27 March 2014 | Journal of Endocrinological Investigation, Vol. 33, No. 6Failure of rituximab treatment in a case of severe thyroid ophthalmopathy unresponsive to steroids18 December 2009 | Clinical Endocrinology, Vol. 72, No. 6Ocular treatment of thyroid eye disease9 January 2014 | Expert Review of Ophthalmology, Vol. 5, No. 3Novel ways to attack inflammation in thyroid eye disease9 January 2014 | Expert Review of Ophthalmology, Vol. 5, No. 3Immunopathogenesis of Thyroid Eye Disease: Emerging ParadigmsSurvey of Ophthalmology, Vol. 55, No. 3Graves' OphthalmopathyNew England Journal of Medicine, Vol. 362, No. 8Pathogenesis of Graves’ ophthalmopathyGraves’ OphthalmopathyOcular Surface Effects of Thyroid DiseaseThe Ocular Surface, Vol. 8, No. 1Evidence of orbital B and Tâcell depletion after rituximab therapy in Gravesâ ophthalmopathyActa Ophthalmologica, Vol. 87, No. 8Rituximab in the Treatment of Thyroid Eye Disease: Science Fiction?9 September 2009 | Orbit, Vol. 28, No. 4Rituximab in non-haematological disorders of adults and its mode of actionBritish Journal of Haematology, Vol. 146, No. 3Attenuation of Induced Hyperthyroidism in Mice by Pretreatment with Thyrotropin Receptor Protein: Deviation of Thyroid-Stimulating to Nonfunctional Antibodies23 April 2009 | Endocrinology, Vol. 150, No. 8Treatment of Graves' Hyperthyroidism: Evidence-Based and Emerging ModalitiesEndocrinology and Metabolism Clinics of North America, Vol. 38, No. 2Graves orbitopathy: a perspective7 May 2009 | Nature Reviews Endocrinology, Vol. 5, No. 6Rituximab treatment in a patient with severe thyroid-associated ophthalmopathy: Effects on orbital lymphocytic infiltratesClinical Immunology, Vol. 131, No. 2Graves' OphthalmopathyNew England Journal of Medicine, Vol. 360, No. 10Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodiesClinical Immunology, Vol. 130, No. 3Update in Endocrine AutoimmunityThe Journal of Clinical Endocrinology & Metabolism, Vol. 93, No. 10Biologic Therapeutics in Thyroid-Associated Ophthalmopathy: Translating Disease Mechanism into Therapy Vibhavari Naik, Nicole Khadavi, Milind N. Naik, Cathy Hwang, Robert A. Goldberg, Angelo Tsirbas, Terry J. Smith, and Raymond S. Douglas12 September 2008 | Thyroid, Vol. 18, No. 9Application of New Therapies in Graves' Disease and Thyroid-Associated Ophthalmopathy: Animal Models and Translation to Human Clinical Trials J. Paul Banga, Claus H. Nielsen, Jacqueline A. Gilbert, Daniel El Fassi, and Laszlo Hegedus12 September 2008 | Thyroid, Vol. 18, No. 9Immune Mechanisms in Thyroid Eye Disease Geniece M. Lehmann, Steven E. Feldon, Terry J. Smith, and Richard P. Phipps12 September 2008 | Thyroid, Vol. 18, No. 9Biologic Response Modifiers for OphthalmologistsOphthalmic Plastic & Reconstructive Surgery, Vol. 24, No. 5Novel Immunomodulating Agents for Graves OrbitopathyOphthalmic Plastic & Reconstructive Surgery, Vol. 24, No. 4Perspectives in pharmacological management of Graves’ hyperthyroidism and orbitopathy10 January 2014 | Expert Review of Clinical Immunology, Vol. 4, No. 3New immunomodulators in the treatment of Graves’ ophthalmopathyAnnales d'Endocrinologie, Vol. 69, No. 2Pathogenesis of Graves' Ophthalmopathy: The Role of Autoantibodies Teck Kim Khoo and Rebecca S. Bahn5 November 2007 | Thyroid, Vol. 17, No. 10B-cell depletion with rituximab in the treatment of autoimmune diseases31 July 2007 | Expert Opinion on Biological Therapy, Vol. 7, No. 7B Lymphocyte Depletion with the Monoclonal Antibody Rituximab in Graves’ Disease: A Controlled Pilot StudyThe Journal of Clinical Endocrinology & Metabolism, Vol. 92, No. 5B Cell Depletion in Graves’ Disease: The Right Answer to the Wrong Question?The Journal of Clinical Endocrinology & Metabolism, Vol. 92, No. 5The Use of Biologics and Other Immunosuppressants in the Treatment of Common Inflammatory Diseases in Neuro-ophthalmologyInternational Ophthalmology Clinics, Vol. 47, No. 4Treatment of Graves’ disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open studyEuropean Journal of Endocrinology, Vol. 156, No. 1 Volume 16Issue 7Jul 2006 InformationCopyright 2006, Mary Ann Liebert, Inc.To cite this article:Daniel El Fassi, Claus H. Nielsen, Hans C. Hasselbalch, and Laszlo Hegedüs.Treatment-Resistant Severe, Active Graves' Ophthalmopathy Successfully Treated with B Lymphocyte Depletion.Thyroid.Jul 2006.709-710.http://doi.org/10.1089/thy.2006.16.709Published in Volume: 16 Issue 7: August 4, 2006PDF download